查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1998272

藥物篩檢市場：依技術、藥物類型、檢體類型和最終用戶分類－2026-2032年全球市場預測

Drug Screening Market by Technology, Drug Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物篩檢市場價值將達到 113.6 億美元，到 2026 年將成長至 130.6 億美元，到 2032 年將達到 309.8 億美元，複合年成長率為 15.40%。

主要市場統計數據
基準年 2025 113.6億美元
預計年份：2026年 130.6億美元
預測年份：2032年 309.8億美元
複合年成長率 (%) 15.40%

簡要概述影響藥物篩檢格局演變、相關人員以及檢查室和採購決策的策略挑戰。

由於技術進步、監管預期變化以及應用情境從臨床診斷到職場合規等多元化發展，藥物篩檢領域正經歷快速變革。本概要概述了重塑篩檢專案設計、實施和管治的關鍵因素，並在詳細分析之前提供簡要概述。本概要整合了分析平台、檢體跨境關鍵發展，所有這些都構成了近年來藥物篩檢領域面臨的戰略挑戰。

分析正在重新定義全球藥物篩檢進行和管治方式的關鍵技術、監管和營運變革。

近年來，藥物篩檢生態系統發生了多項變革性變化，重塑了其功能和價值提案。首先，分析儀器的進步提高了檢測靈敏度和特異性，即使在複雜的基質中也能更早、更準確地識別物質。其次，數位化工作流程和實驗室資訊學的整合簡化了端到端流程，縮短了周轉時間，同時提高了資料的完整性和可追溯性。第三，向分散式和就地檢驗模式的轉變擴大了檢測範圍，但也對不熟悉的環境下的檢驗和品質保證提出了新的要求。

評估 2025 年美國關稅變化將如何影響檢查室供應鏈的韌性、籌資策略和營運連續性。

2025年關稅的實施和貿易政策的調整給依賴跨境採購試劑、儀器零件和耗材的製造商、經銷商和檢查室帶來了顯著的摩擦。對於供應鏈跨越多個司法管轄區的機構而言，進口關稅的增加以及由此導致的行政成本上升，使得採購週期延長，並需要重新審視供應商合約和庫存緩衝。在營運層面，實驗室正在透過重新評估其供應商組合、加快替代供應商的認證流程，以及在某些情況下將部分生產活動遷回國內市場來應對這些變化，以降低關稅變化帶來的風險。

將技術、分析物、檢體類型和最終用戶需求與實際檢驗和商業化途徑連結起來的詳細細分分析。

對細分市場的詳細分析揭示了每種技術平台、分析物分類、檢體類型和最終用戶類別的不同促進因素，這些因素決定了其應用管道和價值提案。從技術角度來看，層析法平台仍然是確證檢測的核心。氣相層析法在揮發性分析物方面表現出色，而液相層析法則廣泛適用於極性和非極性化合物。免疫檢測提供高性能的篩檢能力，化學冷光提高了靈敏度，而酵素連結免疫吸附試驗（ELISA）和螢光法則具有成本效益高的可擴展性。質譜分析，特別是用於揮發性和熱穩定性化合物的氣相層析法-質譜聯用技術，以及用於多成分分析的液相層析法-串聯式質譜質譜聯用技術，正日益被視為最終鑑定的黃金標準。這些平台之間的轉換通常需要在處理能力、靈敏度和操作複雜性之間進行權衡。

這項區域比較分析概述了管理體制、採購模式和基礎設施的差異如何推動世界主要地區採取不同的部署策略。

區域趨勢持續影響技術應用、監管重點和商業策略，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，完善的檢查室基礎設施和一體化的醫療保健系統為高效能確認平台的快速部署提供了支持，而監管機構則優先考慮臨床有效性和資料互通性。此外，該地區私營部門對職場和消費者檢測解決方案的高度參與，正在推動競爭性的商業化模式和服務多元化。

策略競爭格局概述，重點在於影響市場定位的創新叢集、夥伴關係模式和服務導向業務轉型。

藥物篩檢生態系統的競爭趨勢以儀器和檢測化學領域的密集創新以及融合檢測、資訊學和合規性支持的服務經濟的擴張為特徵。主要企業正投資於支援高效能篩檢和確證分析的模組化平台，而其他企業則透過整合軟體解決方案來增強結果解讀和管理的監管鏈，從而實現差異化競爭。儀器製造商和試劑供應商之間的策略合作夥伴關係日益普遍，以確保相容性並縮短新檢測方法的檢驗時間。

清晰、優先的營運和策略建議，領導者可以實施這些建議，以加快採用速度、降低風險並增強長期競爭力。

行業領導企業應優先採取一系列切實可行的措施，以確保在快速變化的環境中保持競爭優勢和業務永續營運。首先，企業應使其產品開發藍圖與已驗證的臨床和法醫學要求保持一致，並檢驗嚴格的性能測試，以預測監管預期和最終用戶的工作流程。其次，企業應將供應鏈多元化和策略庫存管理作為降低風險的核心實踐，並制定應對關稅波動、零件短缺和物流中斷等情況的情境計畫。

本報告對混合方法研究途徑、檢驗程序和局限性進行了透明的解釋，這些解釋了本報告中基於證據的結論的基礎。

本報告的研究透過結合實地研究（對專家和最終用戶進行定性訪談）、整合結構化二手資訊以及嚴格的交叉檢驗，確保了研究結果的可靠性和可操作性。主要調查方法包括訪談檢查室管理人員、採購負責人、監管專家和技術供應商，以了解實際限制、採購標準和檢驗經驗。二手研究涵蓋了同行評審文獻、監管指南、技術白皮書和供應商提交的檢驗摘要，所有這些資料都經過系統評估，以確保其相關性和方法論的嚴謹性。

這些結論融合了技術、營運和監管方面的主題，為組織決策和投資提供了切實可行的藍圖。

總之，當前藥物篩檢領域的特點是技術快速融合、監管預期不斷變化以及供應鏈脆弱性日益增加。這些因素在為企業差異化發展提供機會的同時，也為營運連續性帶來挑戰。那些能夠取得卓越成果的機構，往往是那些投資於檢驗且可互通的技術、建立穩健的採購和維護體系，並將分析技術的進步轉化為清晰的使用者價值提案，並應用於臨床、法醫學、職場和消費者等各個領域。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：藥物篩檢市場：依技術分類

  • 層析法
    • 氣相層析法
    • 液相層析法
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酶聯螢光光譜法
    • 酵素免疫分析法
  • 質譜分析
    • 氣相層析法聯用
    • 液相層析法-串聯式質譜質譜法

第9章：藥物篩檢市場：依藥物類型分類

  • 安非他命
  • 古柯鹼
  • 鴉片類藥物
    • 可待因
    • 海洛因
    • 氫可酮
  • 天使塵PCP
  • 四氫大麻酚

第10章 藥物篩檢市場：依檢體類型分類

  • 血
  • 頭髮
  • 口腔液
  • 唾液
  • 尿

第11章 藥物篩檢市場：依最終使用者分類

  • 臨床檢查室
  • 藥物治療中心
  • 刑事鑑定實驗室
  • 家庭檢查室
  • 職場檢查室

第12章 藥物篩檢市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：藥物篩檢市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 藥物篩檢市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國藥物篩檢市場

第16章：中國藥物篩檢市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • Laboratory Corporation of America Holdings
  • OraSure Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Revvity, Inc.
  • Roche Holding AG
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-DD6333AE5B92

The Drug Screening Market was valued at USD 11.36 billion in 2025 and is projected to grow to USD 13.06 billion in 2026, with a CAGR of 15.40%, reaching USD 30.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.36 billion
Estimated Year [2026] USD 13.06 billion
Forecast Year [2032] USD 30.98 billion
CAGR (%) 15.40%

Concise framing of the evolving drug screening environment, stakeholders, and the strategic questions driving laboratory and procurement decisions

The drug screening landscape is undergoing rapid evolution driven by technological progress, shifting regulatory expectations, and growing diversity in use cases ranging from clinical diagnostics to workplace compliance. This executive brief introduces the core forces reshaping how screening programs are designed, executed, and governed, offering readers a concise orientation before deeper analysis. It synthesizes key developments across analytical platforms, specimen handling practices, end-user requirements, and cross-border trade influences that together define near-term strategic imperatives.

Beginning with a clear statement of scope and objectives, this introduction frames the subsequent sections by identifying the principal stakeholders-laboratories, manufacturers, healthcare providers, employers, and regulators-and the decisions they face. The narrative emphasizes the interconnectedness of technology selection, sample workflow, and regulatory adherence while highlighting the commercial pressures that drive innovation adoption. Finally, it outlines the methodological approach and the types of evidence used to derive insights, ensuring readers understand the basis for the conclusions and recommendations that follow.

Analysis of the major technological, regulatory, and operational shifts that are redefining how drug screening is performed and governed globally

Recent years have produced several transformative shifts that are redefining the drug screening ecosystem, altering both capability and value propositions. First, advances in analytical instrumentation have accelerated detection sensitivity and specificity, enabling earlier and more accurate identification of substances across complex matrices. Second, the integration of digital workflows and laboratory informatics is streamlining end-to-end processes, reducing turnaround times while improving data integrity and traceability. Third, the movement toward decentralized and point-of-care testing formats has expanded access but has also created new validation and quality-assurance requirements for non-traditional settings.

Concurrently, regulatory landscapes are becoming more dynamic, with authorities refining standards for assay performance, chain-of-custody, and result reporting to match technological possibilities and public health needs. Supply chain resilience has emerged as a strategic priority, prompting manufacturers and service providers to diversify sourcing and inventory strategies. Finally, stakeholder expectations around transparency and clinical relevance are raising the bar for both analytical outcomes and the contextual interpretation of results. Taken together, these shifts necessitate adaptive strategies that balance innovation adoption with rigorous validation and operational scalability.

Assessment of how 2025 tariff shifts in the United States are reshaping supply chain resilience, procurement strategies, and operational continuity in laboratories

The introduction of tariffs and trade policy adjustments in 2025 has created measurable friction for manufacturers, distributors, and laboratories that depend on cross-border sourcing of reagents, instrumentation components, and consumables. For organizations whose supply chains span multiple jurisdictions, increased import duties and associated administrative costs have lengthened procurement cycles and necessitated revisions to supplier contracts and inventory buffers. At the operational level, laboratories are responding by reassessing vendor portfolios, accelerating qualification of alternate suppliers, and in some cases repatriating certain manufacturing activities to reduce exposure to tariff volatility.

Beyond procurement, tariffs have influenced pricing negotiations and capital-expenditure decisions. Buyers are weighing the total cost of ownership for instruments that may now carry incremental import costs, and service providers are recalibrating pricing models to preserve margins without compromising quality. Indirect consequences are also evident: extended lead times are prompting laboratories to optimize predictive ordering and to invest in maintenance and spares strategies that maintain continuity of testing services. In summary, policy shifts have elevated supply chain management from a tactical function to a strategic competency that directly impacts operational resilience and cost structures.

In-depth segmentation analysis linking technologies, analyte targets, sample types, and end-user requirements to practical validation and commercialization pathways

A granular view of segmentation reveals differentiated drivers across technology platforms, analyte classes, specimen types, and end-user categories that determine adoption pathways and value propositions. On the technology axis, chromatography platforms remain central for confirmatory testing, with gas chromatography providing strength in volatile analytes and liquid chromatography offering broad applicability across polar and nonpolar compounds; immunoassays deliver high-throughput screening capability with chemiluminescent approaches offering sensitivity gains while ELISA and fluorescent formats provide cost-effective scalability; mass spectrometry techniques, notably gas chromatography mass spectrometry for volatile and thermal-stable compounds and liquid chromatography-tandem mass spectrometry for multi-analyte panels, are increasingly the gold standard for definitive identification. Transitioning between these platforms often involves trade-offs between throughput, sensitivity, and operational complexity.

When examining drug type segmentation, traditional panels continue to emphasize stimulants, depressants, and cannabinoids, with amphetamines and cocaine requiring robust confirmatory workflows, while opiates-subdivided into codeine, heroin, and morphine-demand assays that distinguish metabolites and account for cross-reactivity. Phencyclidine and tetrahydrocannabinol remain important targets for both forensic and clinical use cases. Sample type segmentation drives procedural design: blood and urine remain foundational for clinical accuracy and historical comparability, hair provides extended detection windows suitable for forensic timelines, and oral fluid and saliva facilitate noninvasive, on-site screening with implications for chain-of-custody and confirmatory testing. End-user segmentation highlights distinct requirements: clinical laboratories prioritize diagnostic validity and integration with electronic health records, drug treatment centers focus on longitudinal monitoring and patient engagement, forensic laboratories emphasize evidentiary rigor and courtroom defensibility, home testing demands user-friendly interfaces and clear instructions, and workplace testing balances speed with legal compliance. Understanding how these segments interact is essential for tailoring product development, validation protocols, and commercial strategies.

Comparative regional intelligence outlining how regulatory regimes, procurement models, and infrastructure differences drive distinct adoption strategies across major global regions

Regional dynamics continue to shape technology uptake, regulatory priorities, and commercial strategies, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory infrastructure and integrated healthcare systems support rapid adoption of high-performance confirmation platforms, while regulatory bodies emphasize clinical validity and data interoperability. This region also demonstrates a high degree of private-sector involvement in workplace and consumer testing solutions, which drives competitive commercialization models and service diversification.

Across Europe, Middle East & Africa, regulatory frameworks are heterogeneous, prompting manufacturers and service providers to prioritize adaptable products that can meet divergent compliance requirements. Investment in forensic capabilities is growing in several markets, and public-health initiatives are influencing the types of assays prioritized for screening programs. In the Asia-Pacific region, a mix of mature and emerging markets is accelerating demand for scalable, cost-efficient solutions; local manufacturing capabilities and government-led procurement strategies shape pricing and distribution dynamics. Cross-region collaboration and knowledge exchange are increasingly important as stakeholders seek harmonized best practices that balance local regulatory constraints with international analytical standards.

Strategic competitive overview highlighting innovation clusters, partnership models, and service-oriented business transformations that influence market positioning

Competitive dynamics in the drug screening ecosystem are characterized by concentrated innovation in instrumentation and assay chemistries, alongside a proliferating services economy that bundles testing, informatics, and compliance support. Leading organizations are investing in modular platforms that accommodate both high-throughput screening and confirmatory analyses, while others are differentiating through integrated software solutions that enhance result interpretation and chain-of-custody management. Strategic collaborations between instrument manufacturers and reagent suppliers are becoming more common to ensure compatibility and to accelerate time-to-validation for new assays.

Mergers, strategic partnerships, and targeted acquisitions continue to reshape the competitive landscape as companies seek capabilities in high-demand areas such as mass spectrometry, point-of-care diagnostics, and laboratory automation. Additionally, investments in regulatory science and clinical validation studies serve as durable barriers to entry, particularly in sectors where forensic defensibility or clinical accreditation is required. Finally, service-oriented business models that offer managed testing and subscription-based access to analytic capacity are increasing market reach, enabling smaller laboratories and non-traditional end users to access advanced testing modalities without large capital expenditures.

Clear and prioritized operational and strategic recommendations that leaders can implement to accelerate adoption, reduce risk, and strengthen long-term competitiveness

Industry leaders should prioritize a set of actionable measures to secure competitive advantage and operational resilience in a rapidly evolving environment. First, firms must align product development roadmaps with validated clinical and forensic requirements, investing in rigorous performance studies that anticipate regulatory expectations and end-user workflows. Second, supply chain diversification and strategic inventory management should be elevated to core risk-mitigation practices, with scenario planning for tariff fluctuations, component shortages, and logistics disruptions.

Third, adoption of digital laboratory information systems and analytics should be accelerated to improve throughput, ensure data integrity, and enable predictive maintenance of critical instrumentation. Fourth, organizations should pursue modular business models that combine hardware, consumables, and services to create recurring revenue streams and to lower adoption barriers for decentralized users. Fifth, stakeholders must invest in workforce training and certification programs that maintain proficiency as technologies evolve. Finally, proactive engagement with policymakers, accreditation bodies, and professional associations will help shape practical regulatory frameworks and standards, reducing uncertainty for innovators and purchasers alike.

Transparent explanation of the mixed-methods research approach, validation steps, and limitations that underpin the report's evidence-based conclusions

The research behind this report combines primary qualitative engagements with subject-matter experts and end users, structured secondary-source synthesis, and rigorous cross-validation to ensure robust and actionable findings. Primary inputs included interviews with laboratory directors, procurement leads, regulatory specialists, and technology vendors to capture real-world constraints, procurement criteria, and validation experiences. Secondary research encompassed peer-reviewed literature, regulatory guidances, technical whitepapers, and provider-submitted validation summaries, all systematically evaluated for relevance and methodological rigor.

Data triangulation techniques were used to reconcile discrepancies between public literature and practitioner accounts, and sensitivity checks were applied to qualitative conclusions to ensure they were not driven by isolated anecdotes. Where applicable, case studies illustrating deployment pathways, supply chain adjustments, and validation timelines were developed to anchor recommendations. Finally, the methodology acknowledges limitations: respondent samples may over-represent early adopters, and rapid technological change can shorten the shelf life of tactical recommendations. To mitigate these risks, the study emphasizes strategic principles and process-oriented recommendations designed to remain relevant across expected technology trajectories.

Concluding synthesis that ties together technological, operational, and regulatory themes into a pragmatic blueprint for organizational decision-making and investment

In closing, the contemporary drug screening landscape is defined by accelerated technological convergence, shifting regulatory expectations, and heightened supply chain sensitivity. These forces create both opportunities for differentiation and challenges to operational continuity. Organizations that excel will be those that invest in validated, interoperable technologies; that build resilient procurement and maintenance capabilities; and that translate analytical advances into clear user-value propositions across clinical, forensic, workplace, and consumer contexts.

Looking forward, the capacity to integrate high-sensitivity confirmatory tools with efficient screening workflows, supported by robust informatics and quality systems, will determine which providers lead in both performance and scale. Stakeholders should interpret the findings herein as a strategic blueprint for aligning investment, operations, and policy engagement to achieve measurable improvements in test reliability, turnaround, and cost-efficiency. The recommendations provided are intended to guide pragmatic action while remaining adaptable to emerging innovations and regulatory developments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Screening Market, by Technology

  • 8.1. Chromatography
    • 8.1.1. Gas Chromatography
    • 8.1.2. Liquid Chromatography
  • 8.2. Immunoassay
    • 8.2.1. Chemiluminescent Immunoassay
    • 8.2.2. Enzyme-Linked Fluorescent Assay
    • 8.2.3. Enzyme-Linked Immunosorbent Assay
  • 8.3. Mass Spectrometry
    • 8.3.1. Gas Chromatography Mass Spectrometry
    • 8.3.2. Liquid Chromatography-Tandem Mass Spectrometry

9. Drug Screening Market, by Drug Type

  • 9.1. Amphetamines
  • 9.2. Cocaine
  • 9.3. Opiates
    • 9.3.1. Codeine
    • 9.3.2. Heroin
    • 9.3.3. Morphine
  • 9.4. Phencyclidine
  • 9.5. Tetrahydrocannabinol

10. Drug Screening Market, by Sample Type

  • 10.1. Blood
  • 10.2. Hair
  • 10.3. Oral Fluid
  • 10.4. Saliva
  • 10.5. Urine

11. Drug Screening Market, by End User

  • 11.1. Clinical Laboratories
  • 11.2. Drug Treatment Centers
  • 11.3. Forensic Laboratories
  • 11.4. Home Testing
  • 11.5. Workplace Testing

12. Drug Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drug Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Drug Screening Market

16. China Drug Screening Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Danaher Corporation
  • 17.10. Eurofins Scientific SE
  • 17.11. Laboratory Corporation of America Holdings
  • 17.12. OraSure Technologies, Inc.
  • 17.13. Quest Diagnostics Incorporated
  • 17.14. Revvity, Inc.
  • 17.15. Roche Holding AG
  • 17.16. Siemens Healthineers AG
  • 17.17. Sysmex Corporation
  • 17.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. G7 DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)